Home Cart Sign in  
Chemical Structure| 1333316-35-0 Chemical Structure| 1333316-35-0

Structure of 1333316-35-0

Chemical Structure| 1333316-35-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of [ 1333316-35-0 ]

CAS No. :1333316-35-0
Formula : C15H13Br2N
M.W : 367.08
SMILES Code : CC1(C)C2=C(C=CC(Br)=C2)NC3=CC=C(Br)C=C13
MDL No. :MFCD26402967
InChI Key :OJDIPHRGWNTBOO-UHFFFAOYSA-N
Pubchem ID :67414167

Safety of [ 1333316-35-0 ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Computational Chemistry of [ 1333316-35-0 ] Show Less

Physicochemical Properties

Num. heavy atoms 18
Num. arom. heavy atoms 12
Fraction Csp3 0.2
Num. rotatable bonds 0
Num. H-bond acceptors 0.0
Num. H-bond donors 1.0
Molar Refractivity 86.83
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

12.03 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

3.23
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

5.72
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

5.21
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

5.01
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

5.11
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

4.86

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-6.21
Solubility 0.000225 mg/ml ; 0.000000613 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Poorly soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

-5.74
Solubility 0.000669 mg/ml ; 0.00000182 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Moderately soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-7.65
Solubility 0.00000816 mg/ml ; 0.0000000222 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Poorly soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

Yes
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

Yes
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

Yes
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

Yes
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

No
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

No
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-4.48 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

1.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

2.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.55

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

0.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<2.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

2.68

Application In Synthesis of [ 1333316-35-0 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 1333316-35-0 ]

[ 1333316-35-0 ] Synthesis Path-Upstream   1~5

  • 1
  • [ 6267-02-3 ]
  • [ 1333316-35-0 ]
YieldReaction ConditionsOperation in experiment
90% With bromine In chloroform for 8 h; Inert atmosphere Under a nitrogen atmosphere (N2 purging), Compound 1D(2.7 g, 12.93 mmol) was added to chloroform(200ml), followed by stirring. After stirring, 3 equivalents of bromine were slowly added dropwise. After 8 hours, the reaction was quenched by addition of an aqueous sodium thiosulfate solution. Then, extraction was performed. Thereafter, purification was performed using a column using a developing solvent of methylenechloride(MC):hexane (1:5) to obtain a white solid 1E(4.24 g, yield 90percent).
69% With phenyltrimethylammonium tribromide In tetrahydrofuran at 20℃; To a stirred solution of 9,9-dimethyl- 10H- acridine (4, 0.50 g, 2.4 mmol) in dry THF (10 mL), was added trimethylphenylammonium tribromide (PTT) (1.8 g, 4.8 mmol) in one portion. The reaction mixture was stirred overnight at room temperature. After the reaction was judged complete (TLC), the reaction mixture was poured in water (30 mL) and extracted with EtOAc (2 x 30 mL). The combined organic layers were dried over anhydrous MgS04, filtered and evaporated under reduced pressure. The crude product was purified by silica gel column chromatography with gradient elution (0 to 30percent EtOAc-hexane) to afford the title compound as a light brown oil (0.6 g, 69percent yield). 1H NMR (300 MHz, DMSO- 6) δ 1.47 (s, 6 H) 6.74 (d, J=8.48 Hz, 2 H) 7.22 (dd, J=8.48, 2.26 Hz, 2 H) 7.46 (d, J=2.07 Hz, 2 H) 9.18 (s, 1 H). LCMS (ESI) m/z 368 (MH+).
References: [1] Patent: US2018/166636, 2018, A1, . Location in patent: Paragraph 0115; 0116.
[2] Patent: WO2014/165307, 2014, A2, . Location in patent: Paragraph 0321.
  • 2
  • [ 128-08-5 ]
  • [ 6267-02-3 ]
  • [ 1333316-35-0 ]
References: [1] Patent: US2012/319052, 2012, A1, .
  • 3
  • [ 91-40-7 ]
  • [ 1333316-35-0 ]
References: [1] Patent: WO2014/165307, 2014, A2, .
[2] Patent: US2018/166636, 2018, A1, .
  • 4
  • [ 35708-19-1 ]
  • [ 1333316-35-0 ]
References: [1] Patent: WO2014/165307, 2014, A2, .
[2] Patent: US2018/166636, 2018, A1, .
  • 5
  • [ 73183-55-8 ]
  • [ 1333316-35-0 ]
References: [1] Patent: WO2014/165307, 2014, A2, .
[2] Patent: US2018/166636, 2018, A1, .
 

Historical Records

Technical Information

Categories

Related Functional Groups of
[ 1333316-35-0 ]

Bromides

Chemical Structure| 1187830-63-2

A111608 [1187830-63-2]

6-Bromo-4,4-dimethyl-1,2,3,4-tetrahydroquinoline hydrochloride

Similarity: 0.93

Chemical Structure| 946837-99-6

A129173 [946837-99-6]

6-Bromo-4-methyl-1,2,3,4-tetrahydroquinoline

Similarity: 0.93

Chemical Structure| 70173-54-5

A100187 [70173-54-5]

9-Bromo-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinoline

Similarity: 0.88

Chemical Structure| 21865-50-9

A210119 [21865-50-9]

6-Bromo-2,3,4,9-tetrahydro-1H-carbazole

Similarity: 0.88

Chemical Structure| 1259224-11-7

A255725 [1259224-11-7]

5-Bromo-2,3-diphenyl-1H-indole

Similarity: 0.88

Related Parent Nucleus of
[ 1333316-35-0 ]

Acridines

Chemical Structure| 6267-02-3

A275348 [6267-02-3]

9,9-Dimethyl-9,10-dihydroacridine

Similarity: 0.79

Chemical Structure| 578-95-0

A120093 [578-95-0]

Acridin-9(10H)-one

Similarity: 0.59

Chemical Structure| 38609-97-1

A266566 [38609-97-1]

2-(9-Oxoacridin-10(9H)-yl)acetic acid

Similarity: 0.53

Chemical Structure| 88377-31-5

A110274 [88377-31-5]

5-Methoxy-9-oxo-9,10-dihydroacridine-4-carboxylic acid

Similarity: 0.52

Chemical Structure| 7497-52-1

A205854 [7497-52-1]

2-Chloroacridin-9(10H)-one

Similarity: 0.51